2026-08-10-RMB 2.5 Trillion Massive Volume Game: Severe High-Level Reshuffle in CPO, Capital Aggressively Attacks Pharma and Low-Lying Catch-Up Stocks

📊 Market Snapshot

• Shanghai Composite (SSE): 3966.59 (+0.67%)

• Total Market Turnover: 25231.03亿

• Advance / Decline: 4067 / 1391

• Limit-Up / Limit-Down / Failed Board: 99 / 5 / 14

🔍 Top 20 Stocks by Turnover

🏆 Concept Sector Analysis

No data available

Top Gainers Within Each Sector

No data available

💥 Limit-Up Stocks

💔 Failed Limit-Up Stocks

🚀 Dragon-Tiger Board

Hot Limit-Up Pool

No data available

🤖 AI Deep Analysis & Insights

🚩 Market Sentiment Diagnosis

Today, A-shares exhibited a typical pattern of “massive volume volatility and intense high-to-low sector switching.” Total market turnover surpassed RMB 2.52 trillion, with the Shanghai Composite Index closing up 0.67% at 3,966.59 points. Over 4,000 stocks advanced across the market (advancers/decliners ratio at 4,067/1,391). 99 stocks hit limit-up, while only 5 hit limit-down. The failed limit-up rate was controlled at a low level of 12.4%, indicating extremely strong overall market absorption capacity, with sentiment remaining in the strong profit-making effect zone.

However, internal capital competition reached a fever pitch: core high-level AI/CPO and computing power hardware represented by Zhongji Innolight (RMB 45.7B), Eoptolink (RMB 26.6B), and Cambricon (RMB 23.7B) suffered high-volume pullbacks (declines of 5% to 7%), with high-level profit-taking being concentratedly realized. In stark contrast, funds flowed seamlessly into low-lying pharmaceuticals & biotechnology, general consumer goods, and resources sectors. Current market phase definition: Main upward trend phase amid divergence during a massive-volume high-to-low switching period.

💰 Core Mainline & Capital Flows

1. Hot Sectors & Capital Flows

Two opposing forces are clearly visible from the [Top 20 by Turnover] and the [Limit-Up Pool]:

• Capital Siphoning Side (CPO/AI Hardware): Tech giants such as Zhongji Innolight, Eoptolink, Cambricon, and GigaDevice experienced massive volume volatility, signalling clear reduction of short-term positions.
• Capital Attracting Side (Pharma & Biotech / CXO / Pharmaceutical Commerce): Stocks like Baihua Pharmaceutical (5 consecutive limit-ups), Kaikai Real Estate (3 consecutive limit-ups), Acrobiosystems (20cm 2 consecutive limit-ups), Bide Pharmatech (20cm 2 consecutive limit-ups), and WuXi AppTec (turnover over RMB 20.4 billion, surging 4.21%) triggered a limit-up wave. The pharma sector, due to over-adjustment, high valuation safety margins, and defensive attributes, has become the strongest “high fault-tolerant absorption basin” for high-level profit-taking capital.
• Auxiliary Mainline (Resources / Pro-cyclical): Commodities themes such as Zhaojin Gold (2 consecutive limit-ups), China Tungsten & High-tech (+8.64%), and Huayu Mining gained catch-up gains from capital spillover.

2. Market Style Assessment

The market presents a style of “resonance between theme catch-up rallies and weight-stock absorption.” It is not merely micro-cap stock speculation; large-capacity names (such as WuXi AppTec, Fenghua Advanced, Sinoma Science/Guoci Materials) were also heavily bought by institutional capital, showing that mainstream funds are still launching attacks on high fault-tolerant low-lying directions while controlling drawdowns.

🪜 Consecutive Limit-Up Ladder & Space Gaming

1. Consecutive Limit-Up Ladder Mapping

• Highest Ladder (5 Consecutive Limit-Ups):
  • Baoding Technology (5 Consecutive Limit-Ups / 6 Limit-Ups in 7 Days): Electronics/components attribute, the last surviving consecutive limit-up stock in high-level tech territory, with sufficient turnover, exhibiting strong speculative stock group-buying characteristics.
  • Baihua Pharmaceutical (5 Consecutive Limit-Ups): Absolute emotional leader of the pharma sector, pushed up via volume-shrinkage one-word limit-ups, directly anchoring the bounce height for the entire pharma and biotech sector.
• Mid-Tier Ladder (2-3 Consecutive Limit-Ups):
  • Kaikai Real Estate (3 Consecutive Limit-Ups): Pharmaceutical commerce leader, forming ladder support.
  • 2-Limit-Up Ladder: Exhibiting a pattern where “pharma accounts for half the sky” (Acrobiosystems 20cm, Bide Pharmatech 20cm, Harbin Pharmaceutical, Yuheng Pharmaceutical, Ha Sanlian, etc.), combined with Zhaojin Gold (defensive/resources) and Leadmicro (semiconductor position-taking), presenting a very complete progressive ladder.

2. Failed Limit-Up Pool Signal Interpretation

There were 14 stocks in the failed limit-up pool, with a failure rate of only 12.4%. Stocks that failed to hold limit-up such as Gempharmatech (+12.25%), Novoprotein (+17.51%), and Zhejiang Hisun Pharmaceutical belong to healthy turnover divergence after pushing higher in pharma. Under massive trading volume, failed limit-ups did not trigger panic selling; instead, they provided follow-up space for the next day after sufficient turnover of floating shares.

⚡ Key Individual Stock Abnormality Analysis

1. Zhongji Innolight (300308): Turnover reached a record RMB 45.764 billion, closing down 6.01%.
   • Logical Inference: As the overall leader of the CPO sector, blasting out a massive volume bearish candle at a high price level represents a typical high-level institutional/hot money profit realization. Its short-term adjustment signals that the tech mainline has entered a shakeout/consolidation period of “separating the wheat from the chaff.”
2. Baihua Pharmaceutical (600721): 5 limit-ups in 5 days, one-word limit-up, with over RMB 440 million locked in limit-up buying orders.
   • Logical Inference: Absolute leader of the pharma sector. When CPO pulled back, it naturally took over risk-aversion sentiment. Capital locked up at high levels, driving the breakout of the entire innovative drugs, CXO, and pharmaceutical commerce sectors.
3. Acrobiosystems (301080): ChiNext 20cm 2 consecutive limit-ups, turnover RMB 2.265 billion.
   • Logical Inference: High-elasticity runner on the ChiNext board. The logic lies in earnings recovery + pursuit of high elasticity after the pharma sector was over-adjusted; its firm limit-up closing marks high capital preference for 20cm ChiNext low-lying names.
4. Zhaojin Gold (000506): 2 consecutive limit-ups, turnover RMB 2.295 billion.
   • Logical Inference: Dual drivers from safe-haven sentiment and gold prices operating at high levels. During intense volatility in high-level tech stocks, it acted as a “safe haven” attracting defensive funds.

🧭 Next-Day Trading Strategy Recommendations

1. Key Observations for Tomorrow & Risk Prevention

• Points to Observe: Whether CPO leaders (Zhongji Innolight, Eoptolink) can achieve “volume-shrinkage decline cessation” or “stabilize with a lower shadow” the next day. If tech stops falling, the market will enter a healthier dual-mainline rotation; if it continues to fall, guard against catch-up decline risks in high-level, high-valuation names.
• Potential Directions: Low-lying over-adjusted pharma/CXO sectors possess strong potential for “turnover then upward push” after differentiation; additionally, low-lying pro-cyclical (resources/chemicals) and consumer catch-up names deserve attention.

2. Operational Tone

“Control Position & Avoid Highs, Embrace Low Positions”. Under massive volume volatility in the main index, avoid chasing CPO and follower tech stocks that have already achieved high-level consecutive limit-ups. Focus energy on pharma divergence follow-up relays and digging for low-lying, high-elasticity (20cm) first or second limit-up stocks.

3. Operation Guidelines for Key Stocks

• High-Level CPO / Computing Power (e.g., Zhongji Innolight, Cambricon): Partial profit-taking / Wait-and-see. Wait for a daily-level volume-shrinkage bottoming signal; do not rush to bottom-fish on the left side.
• Mainline Pharma Leaders (e.g., Baihua Pharmaceutical, Acrobiosystems): Continue to hold / Take profits in batches on rallies. If Baihua Pharmaceutical opens up its limit, observe turnover absorption; for low-lying over-adjusted pharma stocks that haven’t surged, build positions with attention.
• High-Level Consecutive Limit-Up Speculative Stocks (e.g., Baoding Technology): Take profits on spikes. Divergence at high levels is increasing; avoid locking positions blindly, focus on protecting profits.

注：

1. 数据来源：AKShare。
2. 本文由AI辅助生成，旨在提供市场洞察和数据分析，非投资建议。
3. 声明：投资有风险，入市需谨慎。本文内容仅供参考，不构成任何投资建议或推荐。请根据自身情况做出独立判断。